Program Schedule

Efficacy of Vancomycin against Biofilms of Neonatal Staphylococcus epidermidis Bloodstream Isolates

Session: Poster Abstract Session: Surveillance of Antimicrobial Resistance
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Background: S. epidermidis causes nosocomial infections in neonates and critically ill patients, forming biofilms (BF) on surfaces of intravenous catheters. BF development is a major virulence factor, and BF cells are generally more resistant to antibiotics than their corresponding free-living forms. Our objectives were to a) assess the biofilm-producing capacity of S. epidermidis bloodstream isolates from neonates and b) evaluate the activity of vancomycin (VAN) against S. epidermidis BF.

Methods: BF’s of 7 neonatal S. epidermidis isolates were produced using 96-well microtiter plates. Following appropriate dilutions from overnight cultures grown in TSB medium, 0.2ml of 10^6 bacteria/mL were used to inoculate microtiter wells. After a 24h-incubation at 37oC, the plates were washed with phosphate-buffered saline solution and stained with 1% safranin solution. BF formation was evaluated spectrophotometrically by optical density (OD) measurement at 595nm. The BF producer strain 35983 RP12 was used as control. BF-producing isolates were then incubated with no antibiotic or with VAN at two-fold dilutions of 0.007-256mg/L for an additional 24h, and bacterial damage (BD) was assessed by XTT reduction assay. BF MIC were determined as >50% BD compared to controls. All isolates were studied 4 times with 5 experimental replicates per condition. Differences were compared by ANOVA with Bonferroni post-test.

Results: Two of seven S. epidermidisisolates were strong BF producers (OD>0.270; SP), whereas the remaining five produced BF of intermediate strength (0.14<OD<0.270; IP). Median VAN BF MIC for IP isolates was 32mg/L, the same as that of the control strain (p=ns). Maximum BD for those isolates was 65.6% at 64mg/L. VAN did not reach a BF MIC for SP isolates, as the maximum BD produced was 45% at 128mg/L. Of note, VAN efficacy at higher concentrations tended to decrease (45%-41.1% for SP and 64-60% for IP at 128-256mg/L).

Conclusion: Despite the variable BF production among neonatal S. epidermidis isolates, high MICs were observed for VAN against mature BF of S. epidermidis. Even at very high concentrations, VAN was not totally effective against BF, suggesting difficulty in eradication of S. epidermidisBF.

Funded by NeoVanc European Commission program.

Maria Simitsopoulou, PhD1, Daniela Kyrpitzi1, Virginia Ramos Martin2, William Hope2 and Emmanuel Roilides, MD, PhD3, (1)Pediatrics, Aristotle University of Thessaloniki, Thessaloniki, Greece, (2)Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom, (3)3rd Pediatric Dept., Aristotle University of Thessaloniki, Thessaloniki, Greece


M. Simitsopoulou, None

D. Kyrpitzi, None

V. Ramos Martin, None

W. Hope, None

E. Roilides, None

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, All Rights Reserved.

Follow IDWeek